VolitionRX Advances Liquid Biopsy Technology for Early Cancer Detection and Monitoring

VolitionRX Pioneers Advancement in Liquid Biopsy Technology for Cancer Detection

VolitionRx Limited, a leading epigenetics firm based in Henderson, Nevada, makes substantial progress in liquid biopsy technology, targeting the early detection of cancer and measurable residual disease (MRD). In a significant development, the company recently submits a manuscript detailing a groundbreaking method that isolates and analyzes over 99% pure circulating tumor-derived DNA (ctDNA) from plasma. This innovation positions VolitionRX at the forefront of the diagnostic industry, addressing a total addressable market valued at $36 billion. The ability to effectively identify cancer DNA in blood samples holds immense potential for transforming cancer diagnostics and improving patient outcomes.

Liquid biopsy has traditionally faced challenges due to the prevalence of circulating DNA from non-cancerous cells in the bloodstream. This contamination makes it complex to detect low concentrations of cancer-derived DNA, often leading to false negatives. However, Dr. Jake Micallef, the Chief Scientific Officer of Volition, highlights that the company's novel technique can effectively differentiate cancer DNA from healthy DNA, even when cancer DNA constitutes as little as 1% of the total DNA. Volition's innovative approach leverages a new liquid biopsy chemistry that focuses on CTCF-bound DNA, a biomarker that has shown near exclusivity in cancer patients’ blood plasma. This advancement not only enhances the accuracy of liquid biopsies but also paves the way for more reliable cancer monitoring and treatment effectiveness assessment.

As VolitionRX actively engages with global diagnostic leaders to expedite the commercialization of this promising technology, the implications for early cancer detection become increasingly significant. The company’s work stands to revolutionize the diagnostic landscape by eliminating interference from normal cell-free DNA, offering a potent tool for oncologists in managing patient care. The advancements made by VolitionRX thus signal a critical step forward in the battle against cancer, enhancing the potential for timely and effective interventions for patients worldwide.

In addition to its promising technological advancements, VolitionRX's commitment to collaboration underscores the importance of partnerships in the life sciences sector. Collaborating with established diagnostic leaders is crucial for accelerating the integration of innovative solutions into healthcare systems. Furthermore, the ongoing evolution of epigenetic research positions Volition at a competitive advantage in an ever-growing market, potentially leading to new applications beyond cancer diagnostics in the future. This development not only enhances the company's profile but also contributes significantly to advancements in personalized medicine.